This guidance clarifies the requirements for product name placement, size, prominence, and frequency in promotional labeling and advertisements for prescription drugs. The disclosure of the product name in promotional labeling and advertisements is important for proper identification and to ensure safe and effective use. This guidance also articulates the circumstances under which FDA intends to refrain from taking enforcement action regarding these requirements. We believe that following this guidance will allow for appropriate advertising and promotion without presenting any public health risk to patients.
Artigos recentes
- Quality documentation for medicinal products when used with a medical device- effective from 1/01/2022
- Artificial intelligence in medicine regulation
- Clinical Trial Information System (CTIS) – Sponsor Handbook
- Sistema europeu de ensaios clínicos lançado em janeiro
- EMA new guidelines on veterinary pharmacovigilance
- Veterinary product information templates
- MDCG 2021-19 Guidance note integration of the UDI within an organisation’s quality management system
- The FDA finalized its guidance on the form and content requirements for unique device identifiers (UDI)